Japan's Daiichi Sankyo to acquire US biopharma Ambit Biosciences
September 28, 2014 at 19:32 PM EDT
TOKYO, Sept 29 (Reuters) - Japanese drugmaker Daiichi Sankyo Co Ltd has agreed to acquire U.S. biopharmaceutical company Ambit Biosciences Corp in a deal valued up to $410 million as it looks to build its presence in oncology, the companies said.
